Compare ARMOUR Residential REIT, Inc. (ARR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs GSK plc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.68 (market cap $2.07B), while GSK plc trades at $50.08 (market cap $102.60B). The key difference: GSK plc is far larger — about 49.6× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays the higher dividend (17.28%). Which is the better fit depends on your goals.
| ARR | GSK | |
|---|---|---|
Market Cap | $2.07B | $102.60B |
Sector | Financials | Health |
52-Week High | $19.12 | $61.18 |
52-Week Low | $14.05 | $38.22 |
Dividend Yield | 17.28% | 3.57% |
Enterprise Value | — | $123.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARMOUR Residential REIT (ARR) trades at $16.54, down 0.84% on the day, amid a bearish technical signal. The stock shows a low P/E of 3.78 and trades below book value (P/B 0.91), suggesting potential undervaluation. Recent earnings were mixed, with a Q2 2026 beat but a Q4 2025 miss. The company maintains a high net income margin of 97.43% and consistent dividend payments, with the latest being $0.24 per share. Cash flow from operations improved to $319 million in 2026, though investing outflows remain high.
ARR presents a value opportunity with strong profitability and dividends, but faces risks from volatile earnings, high investing cash outflows, and a bearish technical outlook. Analyst sentiment is mixed, with 60% hold ratings. The stock's appeal hinges on sustained dividend payments and earnings stability amid interest rate sensitivity.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
